The ventromedial nucleus of the hypothalamus (VMH) plays a critical role in regulating systemic glucose homeostasis. How neurons in this brain area adapt to the changing metabolic environment to regulate circulating glucose levels is ill defined. Here, we show that glucose load results in mitochondrial fission and reduced reactive oxygen species in VMH neurons mediated by dynamin-related peptide 1 (DRP1) under the control of uncoupling protein 2 (UCP2). Probed by genetic manipulations and chemical-genetic control of VMH neuronal circuitry, we unmasked that this mitochondrial adaptation determines the size of the pool of glucose-excited neurons in the VMH and that this process regulates systemic glucose homeostasis. Thus, our data unmasked a critical cellular biological process controlled by mitochondrial dynamics in VMH regulation of systemic glucose homeostasis.
Correspondence sabrina.diano@yale.edu
In Brief
To adapt to changing metabolic environments, glucose metabolism in the body is controlled by UCP2-mediated mitochondrial dynamics in a subset of hypothalamic neurons. Toda et al., 2016 , Cell 164, 872-883 February 25, 2016 ª2016 Elsevier Inc. http://dx.doi.org/10.1016/j.cell.2016.02.010
INTRODUCTION
The hypothalamus is an important site for regulation of energy and glucose metabolism (Dietrich and Horvath, 2013; Sandoval et al., 2009) . Homeostatic control of glycemic levels is pivotal not only for preventing seizures, unconsciousness, and brain injury induced by hypoglycemia, but also for protecting the brain from glucose toxicity in diabetes. The ventromedial nucleus of the hypothalamus (VMH) has been recognized as a key region in the regulation of glucose metabolism (Grayson et al., 2013; Morton and Schwartz, 2011) . Glucose-sensing neurons of the VMH are either activated or inhibited by increased glucose levels, and their responses to changes in glucose levels have been shown to be important for the counter-regulatory responses to restore euglycemia following insulin-induced hypoglycemia (Borg et al., 1994; Chan and Sherwin, 2013) and for the secretion of pancreatic insulin in response to increased glucose levels (Kim et al., 2014) . Alteration in mitochondrial dynamics, i.e., mitochondrial fission and fusion, has been observed in metabolic tissues of human and rodent models of diabetes. Whether mitochondrial dynamics in neuronal populations of the VMH is involved in control of systemic glucose homeostasis is still ill defined.
RESULTS

Systemic Glucose Load Induces Mitochondrial Fission in VMH Neurons
To test whether mitochondrial dynamics occur in VMH neurons in response to glucose, we measured mitochondrial size, density, and coverage after glucose or saline administration. We found that systemic glucose administration decreased mitochondrial size ( Figure 1A ) and increased mitochondrial density ( Figure 1B ) in VMH neurons. However, the total mitochondrial area in the cytosol was not changed ( Figure 1C ), indicating that glucose promotes mitochondrial fragmentation (Figures S1A and S1B). Mitochondrial fission is regulated by dynaminrelated peptide 1 (DRP1), of which the active, phosphorylated form is associated with the outer membrane of mitochondria ( Figure 1D ). Western blot analysis showed that glucose administration significantly increased the ratio of pDRP1/DRP1 compared to saline-injected controls (Figures 1E and 1F) , confirming glucose-induced mitochondrial fission in VMH neurons.
Activation of DRP1 Is UCP2 Dependent in the VMH
We have previously shown that increased mitochondria number in neuronal perikarya is promoted by uncoupling protein 2 (UCP2) in the arcuate nucleus (Andrews et al., 2008; Coppola et al., 2007) . UCP2 is also robustly expressed in the VMH (Richard et al., 1998) . Thus, we next tested whether the presence of UCP2 impacts VMH DRP1 phosphorylation in response to a glucose load. To this end, we generated whole-body Ucp2 knockout (Ucp2KO) mice and Ucp2KO mice with selective re-expression of UCP2 in the VMH (Ucp2KOKI Sf1 ). We first generated mice in which a UCP2 coding sequence with CAG promoter and a lox P floxed stop codon (LSL) were inserted into the ROSA26 locus (Ucp2KI fl/fl , Gt(ROSA26-LSL-UCP2-GFP; Figure S2A ). Ucp2KI fl/fl animals were crossed with Ucp2KO mice (Ucp2KOKI fl/fl ). These mice were then crossed with Sf1-cre mice (Dhillon et al., 2006) . In contrast to the increased ratio of pDRP1/DRP1 in control mice, no significant changes were observed in glucose-treated Ucp2KO mice ( Figure 2A ). On the other hand, glucose administration to Ucp2KO mice with selective re-expression of UCP2 in the VMH (Ucp2KOKI Sf1 mice;
Figures S2B and S2D-S2G) significantly increased the pDRP1/DRP1 ratio to levels similar to those observed in control mice ( Figure 2A ). The pDRP1/DRP1 ratio of saline-treated mice was comparable between the three groups ( Figure 2A ). Furthermore, saline-injected mice with selective overexpression of UCP2 in SF1 neurons (Ucp2KI Sf1 mice; Figures S2A, S2C, and S2H-S2K) showed a greater pDRP1/DRP1 ratio compared to saline-treated controls ( Figure 2B ), and glucose administration to Ucp2KI Sf1 mice induced a further increase in the pDRP1/DRP1 ratio compared to their saline group, which was also significantly greater than that observed in glucose-treated controls ( Figure 2B ). These results show that UCP2 is critical for DRP1 phosphorylation in the VMH in response to elevated glucose load.
Mitochondrial Fission Is UCP2 Dependent in the VMH Next, we interrogated whether the control of DRP1 by UCP2 affects mitochondrial adaptations in the VMH in response to glucose. We found that the glucose-administration-triggered alterations in mitochondrial size and density in SF1-positive VMH neurons were not present in Ucp2KO mice ( Figures 2C,  2D , S1C, and S1D). On the other hand, glucose administration significantly reduced mitochondrial size while increasing mitochondrial number in VMH-SF1 neurons of Ucp2KOKI Sf1 (Figure 2F , 2G, S1E, and S1F) and of Ucp2KI Sf1 mice (Figures 2I, 2J, S1G, and S1H), reaching levels similar or greater than those of control mice, respectively. No difference in mitochondrial coverage was found between groups ( Figures 2E, 2H , and 2K). These results, together with the findings on DRP1 phosphorylation, unmasked that UCP2 promotes mitochondrial fission in the VMH in response to systemic glucose load.
Glucose-Induced Neuronal Activation and Decreased ROS Production in the VMH Are UCP2-Dependent We next examined the effect of glucose load on VMH neuronal activation assessed by cfos immunolabeling. Baseline cfos labeling in saline-injected groups was similar ( Figures 3A-3D ). However, after peripheral glucose administration, reduced cfos labeling in SF1 neurons was observed in the VMH of Ucp2KO mice (E and F) Representative western blot (E) and densitometry results (F) for phosphorylation of DRP1 at Ser616 (pDRP1), total DRP1 (DRP1), and b-actin in VMH samples from control mice 30 min after saline (n = 5) or glucose injection (n = 5). All data represent the mean ± SEM; scale bar in (D) represents 500 nm; * = p < 0.05; *** = p < 0.001. Figure 3M ). UCP2 was shown to regulate neuronal activity, in part, by controlling reactive oxygen species (ROS) production (Coppola et al., 2007; Andrews et al., 2008; Diano and Horvath, 2012) . Glucose administration induced a significant elevation of ROS levels in SF1 neurons of Ucp2KO mice compared to controls ( Figures 3N, 3O , and 3R). VMH re-expression of UCP2 was sufficient to reduce ROS to the levels observed in control mice (Figures 3N, 3P, and 3R) .
Glucose administration induced a significant reduction of ROS levels also in VMH neurons of Ucp2KI Sf1 mice, a reduction that was significantly greater than that observed in control mice (Figures 3N, 3Q and 3R) . These results indicate that UCP2 enables VMH neuronal activation in response to a glucose load, in part, by reducing ROS levels.
Systemic Glucose Homeostasis Is Regulated by VMH UCP2
The VMH plays an important role in glucose metabolism. To test whether UCP2 in the VMH has relevance to systemic glucose control, we analyzed glucose homeostasis in control, Ucp2KO, and Ucp2KOKI Sf1 mice (Figure 4 ). Ucp2KO mice displayed decreased glucose tolerance compared to control mice ( Figure 4A ). Selective re-expression of UCP2 in the VMH of Ucp2KOKI Sf1 mice restored glucose tolerance to a level that was not statistically different from that of control mice ( Figure 4A ). No differences in circulating insulin levels were observed between groups ( Figure 4B ). Furthermore, analyses of body weight ( Figure S3A ) and composition (Figures S3B and S3C) and histological analysis of pancreatic b-cells ( Figures S3D-S3H) showed no difference between groups. To assess insulin action, hyperinsulinemic-euglycemic clamp studies were performed ( Figures 4C-4M ). Compared to control and Ucp2KOKI
Sf1 animals, Ucp2KO mice showed significantly lower glucose infusion rate (GIR) to maintain euglycemia ( Figures  4C-4E ), revealing that UCP2 in VMH neurons is required to regulate insulin sensitivity. Endogenous glucose production (EGP) in Ucp2KO mice was higher than controls, and selective VMH re-expression of UCP2 in Ucp2KOKI Sf1 mice partially restored EGP to the level of controls (Figures 4F and 4G) . In addition to the liver, whole body glucose utilization (rate of disappearance; Rd) and rate of glycolysis were significantly lower in Ucp2KO mice than controls and Ucp2KOKI Sf1 mice ( Figures 4H and 4I ). Consistent with this, 2-deoxy-D-glucose (2DG) uptake in muscles and brown adipose tissue (BAT) was significantly lower in Ucp2KO mice compared to controls ( Figures 4J-4M) , and reexpression of UCP2 in SF1 neurons restored them to control levels ( Figures 4J-4M ).
To further analyze the role of VMH UCP2 in glucose homeostasis, we next performed glucose measurements in Ucp2KI Sf1 and control mice. No differences in energy metabolism were observed between Ucp2KI Sf1 mice and their controls ( Figures  S4A-S4H ), including lack of changes in body weight and length ( Figures S4A and S4B ), body fat mass and lean mass ( Figures  S4C and S4D ), food intake ( Figure S4E ), and energy expenditure in Ucp2KI
Sf1 (Figures S4F-S4H ). However, in line with the effect of VMH-UCP2 deletion on glucose homeostasis, significant differences in glucose metabolism were observed between Ucp2KI Sf1 mice and their controls, whereby Ucp2KI Sf1 mice had significantly lower glucose levels during glucose tolerance test (GTT) compared to controls ( Figure 5A ). Measurements of circulating insulin levels during GTT showed no significant differences between the experimental groups ( Figure S4I ), indicating that the increased glucose tolerance was not due to increased insulin secretion. Analysis of insulin sensitivity by insulin tolerance test (ITT) showed that Ucp2KI Sf1 mice were significantly more sensitive to insulin than the controls ( Figure 5B ), indicating that overexpression of UCP2 in the VMH enhances insulin sensitivity without changing body weight and composition and insulin secretion. In agreement with this, Ucp2KI
Sf1 mice had lower gluconeogenic capacity than control mice in a pyruvate tolerance test (PTT; Figure S4J ), which was associated with lower mRNA expression of phosphoenolpyruvate carboxykinase (PEPCK) in the liver ( Figure S4K ). Finally, to determine whether the effect of increased UCP2 expression on glucose metabolism was specific to hyperglycemia, we assessed the effect of glucoprivation, by 2DG injection, in control and Ucp2KI Sf1 mice. No effect of 2DG on glucose metabolism was observed between the groups ( Figure S4L ). Altogether, these data unmasked that UCP2 in VMH neurons is necessary for appropriate physiological regulation of insulin sensitivity in both muscle and liver.
UCP2-Regulated VMH Neuronal Activation Is Critical for the Control of Whole-Body Glucose Metabolism The data above argue for the importance of VMH mitochondrial fission and associated neuronal activation enabled by UCP2 in the physiological control of systemic glucose metabolism. In the VMH, neuronal subpopulations were identified that are either excited or inhibited by glucose (Chan and Sherwin, 2013) . To interrogate whether UCP2 impacts these subpopulations of neurons, we quantified glucose-excited (GE) and glucose-inhibited (GI) neurons in the VMH-SF1 neurons of control and Ucp2KI Sf1 mice. We performed this measurement in the dmVMH since this subdivision showed a larger number of GE neurons as assessed by cfos immunolabeling ( Figure 3M ). We observed that, in Ucp2KI Sf1 mice, the GE neuronal subpopulation was significantly larger (10 GE cells/28 total cells/8 mice) than that of control animals (6 GE cells/32 total cells/7 mice; Figures 5C and 5E).
On the other hand, no differences were found in the GI subpopulation of the dmVMH between transgenic and control animals (control: 2 GI cells/32 total cells/7 mice; Ucp2KI
Sf1
: 3 GI cells/ 28 total cells/8 mice; Figures 5D and 5F ). Furthermore, to determine whether UCP2-mediated increased neuronal excitability to glucose was dependent on K ATP channels, we studied the effect of diazoxide, a K ATP channel opener, on glucose-induced . Altogether, these observations indicate that systemic pDRP1/DRP1 ratio in the experimental groups after glucose administration. Note that pDRP1/DRP1 ratio after saline administration is significantly greater in Ucp2KI Sf1 mice compared to controls.
(C-E) Cumulative probability distribution of cross-sectional mitochondria area (C), mitochondria density (D), and mitochondria coverage (E) in SF1 neurons from Ucp2KO mice injected with either saline or glucose (i.p., 2 g/kg BW). Ucp2KO mice with i.p. saline, n = 395 mitochondria/17 cells/3 mice; Ucp2KO mice with i.p. glucose, n = 437 mitochondria/19 cells/3 mice. (F-H) Cumulative probability distribution of cross-sectional mitochondria area (F), mitochondria density (G), and mitochondria coverage (H) in SF1 neurons from Ucp2KOKI Sf1 mice injected with either saline or glucose (i.p., 2 g/kg BW). (R) Quantification of DHE intensity in SF1 neurons of control mice (n = 4), Ucp2KO mice (n = 5), Ucp2KOKI Sf1 (n = 5), and Ucp2KI Sf1 mice (n = 6).
All data represent the mean ± SEM; * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (B) Plasma insulin concentration during GTT in male control (n = 9), Ucp2KO (n = 6), and Ucp2KOKI Sf1 mice (n = 6).
(C) Blood glucose levels during hyperinsulinemic-euglycemic clamp studies in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups).
(D) Graph showing glucose infusion rate (GIR) required to maintain euglycemia during the clamp period in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups).
(E) Graph showing the average GIR between 70 and 115 min in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups).
(F) Endogenous glucose production (EGP) during both basal and clamp period in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups).
(G) Graph showing the percent-suppression levels of EGP induced by insulin infusion in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups).
(H) Graph showing the rate of glucose disappearance (Rd) during the clamp period, which represents whole body glucose utilization, in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups). Basal Rd is equal to basal EGP.
(I) Graph showing the rates of whole-body glycolysis in control, Ucp2KO, and Ucp2KOKI Sf1 mice (n = 8 per each experimental groups). , and insulin tolerance test (i.p., 1U/kg BW insulin; B), of control (n = 7-9) and Ucp2KI Sf1 mice (n = 7-9).
(C and D) Graphs showing the percent of glucose excited (GE; C) and glucose inhibited (GI; D) SF1 neurons of control (n = 7) and Ucp2KI Sf1 (n = 8) mice.
(E and F) Representative tracers from a GE (E) and a GI (F) neuron from a Ucp2KI Sf1 mouse and a control mouse, respectively.
(G and H) Representative tracers of GE neurons from control (G) and Ucp2KI Sf1 mice (H), respectively, showing that their responses to glucose are dependent of K ATP channels.
(I) Graph showing the percent change of firing rate of dmVMH-GE neurons after the addition in the media of diazoxide (300 mM), a K ATP channel opener. n = 10 cells/5 control mice; n = 11 cells/5 Ucp2KI Sf1 mice.
(J) Graph showing the percent of SF1-GE neurons in the dmVMH of control (8 cells out of 10 in 5 mice total) and Ucp2KI Sf1 mice (9 cells out of 11 in 5 mice total) that were inhibited by diazoxide (300 mM). All data represent the mean ± SEM; (A-C), * = p < 0.05 and ** = p < 0.01 compared to control mice; (I), * = p < 0.05 compared to control in 2.5 mM glucose; # = p < 0.05 compared to Ucp2KI Sf1 in 2.5 mM glucose.
glucose control regulated by UCP2 in the VMH is mediated by VMH-GE neurons. To test this, we selectively interfered with VMH neuronal activation in response to glucose load in freely moving mice using an inhibiting ''designer receptors exclusively activated by designer drugs'' (DREADD) approach (Krashes et al., 2011) . We injected inhibitory DREADD (AAV-hM4Di-mCherry) into the VMH of control (expressing cre in SF1 neurons) and Ucp2KI Sf1 mice, allowing selective and reversible inactivation of SF1 neurons by application of Clozapine-N-oxide (CNO; 0.3 mg/kg body weight [BW] , intraperitoneally [i.p.]). After virus injection into the VMH, locally restricted expression of ''the virus'' was specified by mCherry fluorescence (Figures 6A, 6B , and S5). Thirty minutes after CNO-driven activation of the inhibitory DREADD, glucose was injected and circulating glucose levels measured. Compared to the vehicle-injected mice 30 min prior to glucose administration, control and Ucp2KI
Sf1 mice injected first with CNO and then with glucose ( Figures 6C and 6D ) displayed a significant increase in circulating glucose levels that were similar between these two groups ( Figures 6C and 6D) . Finally, to determine whether UCP2-overexpression-induced increased neuronal excitability to glucose was selective of the VMH, we assessed the effect of UCP2 overexpression in cortical neuronal excitability after a glucose load. First, no difference in cortical cfos staining was observed between control and Ucp2KI Sf1 mice injected either with saline or glucose ( Figures   S6A and S6B) . Furthermore, when Ucp2KI flox/flox mice were injected either with AAV-GFP or AAV-cre-GFP in the cortex (medial parietal associational cortex, MPtA) to generate control and Ucp2KI MPtA mice, respectively, glucose load did not alter cfos immunoreactivity between these two experimental groups or compared to saline-treated groups ( Figures S6C and S6D ), suggesting that UCP2-induced increased neuronal excitability is specific of VMH glucose-sensing neurons. Altogether, these observations provide direct evidence that inhibition of VMH neurons results in impaired glucose uptake in the periphery in response to a glucose load and suggest that UCP2-dependent mitochondrial fission in GE neurons mediates VMH control of systemic glucose metabolism.
DISCUSSION
Our studies show that glucose-induced VMH mitochondrial fission mediated by DRP1 activation and by increased neuronal activation is UCP2 dependent and necessary for the proper control of peripheral glucose metabolism. Whole-body UCP2 knockout (Ucp2KO) mice, in which glucose did not induce these cellular processes, showed glucose intolerance due to reduced insulin sensitivity in peripheral organs. On the other hand, selective re-expression of UCP2 in SF1 neurons (Ucp2KOKI
Sf1
) restored mitochondrial dynamics, DRP1 activation, and neuronal activity after increased glucose levels and re-established insulin sensitivity in peripheral organs. Consistent with these data, mice with selective overexpression of UCP2 (Ucp2KI Sf1 ) in SF1 neurons showed enhanced mitochondrial fission, increased DRP1 activation that resulted in increased VMH neuronal activity, and improved glucose metabolism. Furthermore, when SF1 neurons were selectively inactivated by DREADD, glucose metabolism worsened in both Ucp2KI
Sf1 and control mice. Altogether, our data unmasked that UCP2 in SF1 neurons, by affecting mitochondrial dynamics and neuronal activity, is crucial in the regulation of glucose metabolism of peripheral tissues. The hypothalamus plays a critical role in the homeostatic control of blood glucose levels by altering glucose production in the liver, by altering glucose utilization in peripheral tissues (Grayson et al., 2013) , and by controlling pancreatic secretion of hormones, including insulin (Kim et al., 2014) . Within the hypothalamus, the VMH has been shown to play a critical role in controlling glucose homeostasis via its glucose-sensing neurons. Neurons in the VMH express the inner mitochondrial protein UCP2 (Horvath et al., 1999; Richard et al., 1998) , of which its function in these cells has not been defined.
Previous data from our laboratory have shown that UCP2 expression in arcuate neurons induces mitochondrial changes (Andrews et al., 2008; Coppola et al., 2007 ). The present study shows that UCP2 in VMH neurons also induces mitochondrial changes, i.e., increase in mitochondrial density and reduction in mitochondrial size, suggesting that UCP2 expression is associated with a mitochondrial fission process. In support of this, DRP1 activation, a major component of the mitochondrial fission process (Kasahara and Scorrano, 2014) , was increased in the VMH after glucose administration. UCP2 control of DRP1-dependent fission in VMH neurons is critical for whole-body glucose regulation, since suppression of UCP2 expression in these neurons induced a significant deleterious effect on glucose metabolism, while VMH-UCP2 overexpression significantly improved peripheral glucose metabolism. In accordance with these data, a study from Carneiro and collaborators has shown that intracarotid glucose infusion in rats increases mitochondrial number in the VMH neurons and suppression of this increase attenuates glucose sensing in the VMH neurons (Carneiro et al., 2012) .
Our data show that the activation of VMH neurons, and specifically neurons located in the dmVMH, by UCP2 enhances insulin sensitivity in peripheral tissues. In line with this, intra-VMH injection of leptin, which activates dmVMH-SF1 neurons coexpressing leptin receptors (Dhillon et al., 2006) , enhances insulin sensitivity in both muscles and liver. This occurs through a melanocortin-receptor-dependent pathway in the muscle and a melanocortin-independent pathway in the liver (Toda et al., 2013; Toda et al., 2009 ). In addition, orexin-induced activation of VMH neurons also increases glucose uptake in the muscle ). This activation occurs via the sympathetic nervous system (SNS; Shiuchi et al., 2009 ). On the other hand, regulation of hepatic glucose production by hypothalamic nutrient sensing has been shown to be mediated by the vagus nerve (Lam et al., 2005a (Lam et al., , 2005b . Therefore, it is reasonable to suggest that UCP2-induced VMH activation affects insulin sensitivity in peripheral tissues via the autonomic nervous system. Indeed, SF1-positive fibers have been shown to project to the autonomic centers, such as the hypothalamic paraventricular (PVN) and dorsomedial nuclei (DMH), the periaqueductal gray (PAG), the rostral ventrolateral medulla (RVLM), and the nucleus of the solitary tract (NTS; Lindberg et al., 2013) .
We found that UCP2-induced mitochondrial fission in the VMH affects GE neurons while it does not alter GI neurons. These data suggest that this mechanism is specific for appropriate neuronal responsiveness to hyperglycemia. In support of this, in our study, glucoprivation, induced by 2DG, in Ucp2KI Sf1 mice did not significantly alter glucose metabolism compared to control mice. Furthermore, hypoglycemia and hypoglycemiainduced counter-regulatory responses have been associated with changes in the activity of GI neurons (Fioramonti et al., 2011) .
In summary, our studies revealed a physiological role for UCP2 in the ventromedial SF1 neurons of the hypothalamus in the regulation of glucose homeostasis. This mechanism, by regulating mitochondrial dynamics and the excitability of VMH glucose-sensing neurons, allows the appropriate response to increased glucose levels, resulting in the enhancement in insulin sensitivity in peripheral organs.
EXPERIMENTAL PROCEDURES Animals
All animal work was approved by the Yale University Institutional Animal Care and Use Committee. Mice were housed at 22 C-24 C with a 12 hr light/12 hr dark cycle with standard chow (Harlan Teklad no. 2018, 18% calories from fat) and water provided ad libitum. All mice studied were on a mixed background (129SvEv, FVB, and C57BL/6J).
Generation of Mice Conditionally Expressing UCP2
A construct was engineered in which expression of murine Ucp2 cDNA is controlled by the CAGGS promoter upon Cre-mediated deletion of a transcriptional STOP cassette. A Ucp2 cDNA was introduced into the Asc I site of a STOP-EGFP-ROSA-CAGGS-targeting vector (Sasaki et al., 2006) . This construct was then used to create a knockin at the ROSA locus by homologous recombination in B6;129F1 ES cells, and targeted clones were injected into C57Bl/6 blastocysts to generate mutant mice (Ucp2KI flox/flox mice).
To generate Sf1-neuron-specific overexpression of Ucp2 gene, Ucp2KI flox/flox mice were crossed with Sf1-cre mice, which express cre recombinase in a subset group of neurons of the VMH (Dhillon et al., 2006) . Sf1-cre mice were purchased from the Jackson laboratory (STOCK Tg(Nr5a1-cre)7Lowl/J , either cre positive or negative).
Indirect Calorimetry System and Body Composition
Animals were acclimated in metabolic chambers (TSE System-Core Metabolic Phenotyping Center, Yale University) for 3 days before the start of the recordings. Mice were continuously recorded for 2 days, with the following measurements taken every 30 min: food intake, locomotor activity (in the xy-and z-axes), and gas exchange (O 2 and CO 2 ; TSE LabMaster System). Energy expenditure was calculated according to the manufacturer's guidelines (PhenoMaster Software, TSE System). The respiratory quotient was estimated by calculating the ratio of CO 2 production to O 2 consumption. Values were adjusted by body weight to the power of 0.75 (kg À0.75 ), where mentioned.
Body composition was measured in vivo by MRI (EchoMRI; Echo Medical Systems).
Measurement of Circulating Hormones
Serum from blood samples was obtained by centrifugation at 3,000 rpm for 15 min, and each circulating hormone was determined using a commercially available ELISA kit as follows: insulin (Rat/Mouse Insulin ELISA kit, EZRMI-13K; Millipore) and glucagon (Glucagon Qkit, DGCG0; R&D Systems). All procedures were performed by following the manufacturer's protocol.
Glucose, Insulin, and Pyruvate Tolerance Tests and 2DG Test Glucose tolerance tests were performed in 16-hr-fasted animals as previously reported (Kim et al., 2014; Long et al., 2014) . Each animal received an i.p. injection of 2 g/kg BW glucose (DeltaSelect) in sterile saline. Blood glucose and insulin levels were measured after 15, 30, 60, and 120 min. Insulin-tolerance test was performed in ad libitum fed mice (Kim et al., 2014) . Each animal received an i.p. injection of insulin, 1 U/kg (Humulin R; Eli Lilly). Blood glucose levels were then measured at 15, 30, 60, and 120 min after insulin injection.
PTT was performed in 16-hr-fasted animals. Animals received an i.p. injection of 2 g/kg BW sodium pyruvate (Sigma-Aldrich, Cat#P5280). Blood glucose levels were then monitored at 15, 30, 60, and 120 min after the injection.
The 2DG test was performed by i.p. injection of 200 mg/kg BW 2DG (SigmaAldrich, St. Louis, MO). Blood glucose levels were then monitored at 15, 30, 60, and 120 min after the injection.
Surgical Procedure for Clamp Studies
For the hyperinsulinemic-euglycemic clamp, polyethylene catheters were inserted into the right carotid arteries and jugular veins of mice after they were anesthetized with ketamine (100 mg/kg body mass) and xylazine (10 mg/kg). Animals were individually housed after surgery, and lines were flushed daily with 50 ml heparinized saline for the 3-to 5-days recovery period.
Hyperinsulinemic-Euglycemic Clamp and Measurement of Associated 2-[
C]Deoxy-D-Glucose Uptake
The hyperinsulinemic-euglycemic-clamp protocol was measured as described previously (Ayala et al., 2006; Kim et al., 2014; Long et al., 2014; Toda et al., 2013) and initiated in conscious and unrestrained mice after the fasting for 4 hr. The 90-min basal period (t = À90-0 min) was followed by a 115-min clamp period (t = 0-115 min; Figure 3F) . A priming dose of [3-3 H] glucose (5 mCi; Perkin Elmer) was administered at t = À90 min and was followed by infusion of the tracer at a rate of 0.05 mCi/min for 1.5 hr. For assessment of rate of appearance (Ra) during the basal period, blood samples (50 ml) were collected at t = À15 and À5 min. The clamp period was initiated at t = 0 min by primed and continuous infusion of human insulin (bolus of 8 mU/kg followed by a rate of 1.25 mU kg -1 min -1 for female control, Ucp2KO, and Ucp2KOKI Sf1 mice) (Humulin R; Eli Lilly). The rate of [3-3 H]glucose infusion was increased to 0.1 mCi/min for the remainder of the experiment in order to minimize changes in specific activity relative to the equilibration period. Blood was collected every 5-10 min from the carotid artery catheter, and blood glucose was monitored (One Touch Ultra; Lifescan, Johnson & Johnson). Glucose (30%) was infused at a variable rate via the jugular vein catheter in order to maintain blood glucose levels at 110 to 130 mg/dl. Withdrawn erythrocytes were suspended in sterile 0.9% saline and returned to each animal. Tissue 2DG uptake was measured as described previously (Toda et al., 2013) . For assessment of 2DG uptake, mice were infused 2-[ 14 C]DG (10 mCi) at t = 70 min, and blood samples (50 ml) were collected at t = 75, 85, 95, 105, and 115 min. Immediately after collection of the final blood sample (t = 0 min or 115 min), mice were euthanatized, and soleus, Gastro-R (red portion of gastrocnemius), Gastro-W (white portion of gastrocnemius), interscapular BAT , the heart, the spleen, EWAT (epididymal while adipose tissue), the brain (cortex), and the liver were rapidly dissected. Gastro-R was dissected from the inner surface of gastrocnemius-attaching soleus muscle, while Gastro-W was dissected from the outer surface of the muscle. Rd, which reflects whole-body glucose utilization, Ra, which reflects EGP, and the rates of whole-body glycolysis and glycogen synthesis were determined as described previously (Ayala et al., 2006) .
cfos Immunostaining
After overnight fasting, mice were injected with either saline (same volume as glucose) or glucose (2g/kg, ip) and after 1 hr from the injection they were perfused with saline following 4% paraformaldehyde (PFA) transcardially. Serial sections of the entire VMH were collected 150 mm apart and incubated with the rabbit anti-cfos antibody (Santacruz, 1:2000) , and the mouse anti-mCherry antibody (Life Technologies Corporation, 1:3000) in PB containing 4% normal goat serum, 0.1% glycine, and 0.2% Triton X-100 for 24 hr at room temperature. After several washes with phosphate buffer (PB), sections were incubated in the secondary antibodies (biotinylated goat anti-rabbit immunoglobulin G [IgG] ; 1:250 in PB; Vector Laboratories and goat anti-mouse fluor 633; 1:250 in PB; Life Technologies) for 2 hr at room temperature, then rinsed in PB three times, 10 min each time, and incubated for 2 hr at room temperature with Alexa Fluor 594 streptavidin (Life Technologies, 1:2000 in PB). Sections were mounted on glass slide with vectashield (Vector Laboratories) and analyzed with fluorescent microscope.
DHE Administration
ROS levels in dmVMH-SF1 neurons were measured by injecting dihydroethidium (DHE, 1 mg/mL; Invitrogen) through tail vain (Andrews et al., 2008) . Two hours after the DHE injection, glucose (2 g/kg BW) was injected, and one hour after the glucose injection, mice were anesthetized and transcardially perfused with 0.9% saline with heparin followed by fixative (4% paraformaldehyde, 15% picric acid, 0.1% glutaraldehyde in PBS). Brains were collected and post fixed overnight before coronal sections were taken at every 50 mm. 
Electron Microscopy Analysis
Saline-and glucose-injected (2 g/kg i.p., 1 hr) mice were anesthetized and transcardially perfused with 0.9% saline followed by fixative (4% paraformaldehyde, 15% picric acid, 0.1% glutaraldehyde in 0.1 M PB). Brains were stained with nickeldiaminobenzidine (NicoDAB) by using anti-GFP antibody (1:5000). After several washes with PB, sections were incubated in the secondary antibody (biotinylated goat antirabbit IgG; 1:250 in PB; Vector Laboratories) for 2 hr at room temperature, then rinsed in PB three times, 10 min each time, and incubated for 2 hr at room temperature with avidin-biotinperoxidase (ABC; 1:250 in PB; ABC Elite kit, Vector Laboratories). The immunoreaction was visualized with 3,3-diaminobenzidine (DAB). Sections were then osmicated (1% osmium tetroxide) for 30 min, dehydrated through increasing ethanol concentrations (using 1% uranyl acetate in the 70% ethanol for 30 min), and flat embedded in araldite between liquid-release-coated slides (Electron Microscopy Sciences). After capsule embedding, blocks of the dmVMH were trimmed. Ribbons of serial ultrathin sections were collected on Formvar-coated single slot grids and examined using a Philips CM-10 electron microscope. Mitochondria were counted blindly from randomly selected sections, and ImageJ software was used to normalize cytoplasmic area so that mitochondrial density is expressed as the number of mitochondria per square micrometers of cytosol.
Western Blot Analysis
Protein lysates from hypothalamic VMH punches were prepared by modified RIPA buffer (50 mM Tris-HCl pH (7.5), 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride) supplemented with protease inhibitor cocktail (Roche, Cat# 11 836 170 001) and Halt Phosphatase Inhibitor (product # 78420, Thermo Fisher Scientific) on ice for 30 min, followed by centrifugation at 14,000 rpm for 15 min. Protein concentrations were measured using the BCA kit (Thermo scientific, Cat# 23228 and 1859078). Proteins were resolved on 10% SDS-PAGE and transferred to PVDF membrane (Millipore, Cat# IPVH 15150). Membranes were blocked with 5% dry milk in Tris-buffered saline (TBS; 50mM Tris-HCl pH (7.5), 150mM NaCl) for 1 hr, followed by overnight incubation at 4 C with primary antibodies such as anti- 
Electrophysiology
We used 7-to 8-week-old mice were used and the hypothalamic slices were prepared as described previously (Liu et al., 2011) . Briefly, after mice were anaesthetized with isoflurane and decapitated, the brains were rapidly removed and immersed in cold (4 C) oxygenated high-sucrose solution containing (in mM): sucrose 220, KCl 2.5, NaH 2 PO 4 1.23, NaHCO 3 26, CaCl 2 1, MgCl 2 6, and glucose 10, pH (7.3) with NaOH. After being trimmed to a small tissue block containing the hypothalamus, coronal slices (300 mm thick) were cut on a vibratome and maintained in a holding chamber with artificial cerebrospinal fluid (ACSF, bubbled with 5% CO 2 and 95% O 2 ) containing (in mM): NaCl 124, KCl 3, CaCl 2 2, MgCl 2 2, NaH 2 PO 4 1.23, NaHCO 3 25, and glucose 2.5, (pH) 7.4 with NaOH. After a 1-hr recovery period, slices were transferred to a recording chamber and were constantly perfused with ACSF (33 C) at a rate of 2 mL/min. Perforated patch recording was performed in SF1-GFP neurons of dmVMH under voltage and current clamp. The micropipettes were made of borosilicate glass (World Precision Instruments) with a Sutter micropipette puller (P-97) and back filled with a pipette solution containing (in mM): potassium methanesulfonate 135, MgCl2 2, HEPES 10, EGTA 0.2, Mg-ATP 2, Na 2 -GTP 0.3, Na2-phosphocreatin 10, and amphotericin B (Sigma, final concentration 50 mg/mL), (pH) 7.3 with KOH. Both input resistance and series resistance were monitored throughout the experiments, and the former was partially compensated. Only those recordings with stable series resistance and input resistance were accepted. The membrane and spontaneous action potential were recorded in SF1 neurons under current clamp. We recorded action potential firing for 4-8 min at a glucose concentration of 2.5 mM. When firing was stable, glucose concentration was changed to 0.2 mM for 4 min before a return to 2.5 mM glucose for 6 min.
At the end of the perforated patch recordings, the membrane of every cell was ruptured and whole-cell patch recording was measured to check current-voltage relationship. All data were sampled at 3-10 kHz, filtered at 1-3 kHz, and analyzed with an Apple Macintosh computer using AxoGraph X (AxoGraph Scientific). Statistics and plotting were performed with KaleidaGraph (Synergy software) and Igor Pro (WaveMetrics).
The average firing rate was calculated in the last 2 min of each glucose concentration. Cells with 30% change in firing rate were considered either GE or GI neurons.
To check the involvement of the K ATP channel, perforated patch recording was performed in SF1-GFP neurons as reported above, changing glucose concentration from 2.5 mM to 0.2 mM. Glucose concentration was returned to 2. 5mM for 5-8 min only in cells that responded to decreased glucose concentration by reducing their firing rates (GE neurons). At this point, diazoxide, a K ATP channel opener (Sigma, final concentration 300 mM) was added to the solution. The average firing rate was calculated in the last 3 min of 2.5 mM glucose alone and of 2.5 mM glucose + diazoxide. Data were compared using unpaired t tests, with p < 0.05 considered as a K ATPchannel-mediated GE neuron. All the experiments were performed blindly to the electrophysiologist.
Stereotaxic AAV-DREADD Virus Injection
The AAV5/hSyn-DIO-hM4D-mCherry virus (University of North Carolina VectorCore) was injected bilaterally into the VMH as previously described (Franklin and Paxinos, 2007; Krashes et al., 2011) . We anesthetized 10-to 12-week-old Sf1-cre male mice with 100mg/kg ketamine and 10mg/kg xylazine (i.p.) and placed them in stereotaxic apparatus. A guide cannula with dummy cannula (Plastics One) was inserted into the VMH according to the atlas of Franklin and Paxinos (Franklin and Paxinos, 2007 ; from bregma, anteroposterior: À1.4mm; mediolateral: 0.4mm; dorsoventral: À5.8mm). We administered 0.5 ml of AAV virus (1.0 3 10 12 viral genomes [VG]/mL) at a rate of 33.3 nL/minute using an injector (Plastics One) connected with a Hamilton syringe. At 5 min following the injection (to allow for adequate dispersal and absorption of the virus), the same volume of the virus was injected into the contralateral VMH. Animals were administered an analgesic subcutaneously (4 mg/kg Meloxicam SR LAB, Zoopharm) and given 1 week recovery before a GTT was performed. For the GTT, overnight-fasted mice were injected i.p. with CNO (0.3mg/kg, Sigma-Aldrich). At 30 min after CNO administration, 2 g/kg BW of glucose (DeltaSelect) in sterile saline was i.p. injected, and blood glucose levels were measured after 15, 30, 60, and 120 min.
Stereotaxic Viral Injections in the Cortex
The AAV2-GFP and AAV2-Cre-GFP virus (Vector Biolabs) was injected bilaterally into the MPtA. We anesthetized 8-week-old Ucp2KI flox/flox male mice (n = 3 per group) with 100 mg/kg ketamine and 10 mg/kg xylazine (i.p.) and placed them in stereotaxic apparatus. A guide cannula with dummy cannula (Plastics One) was inserted into the MPtA according to the atlas of Franklin and Paxinos (Franklin and Paxinos, 2007 ; from bregma, anteroposterior: À1.4mm; mediolateral: À1mm; dorsoventral: À1mm), and 0.5 ml of either AAV2-GFP virus (1.0 3 10 12 VG/mL) or AAV2-Cre-GFP virus (1.0 3 10 12 VG/mL) was administered using an injector (Plastics One) connected with a Hamilton syringe at a rate of 33.3 nL/minute. After 10 days, mice were fasted overnight and injected the morning after with either saline (same volume as glucose) or glucose (2 g/kg i.p.) and transcardially perfused (as described above) 1 hr from the injection. Brain sections were then stained for cfos and analyzed as described above.
Statistical Analysis
All analyses were performed blinded to the individual performing the experiment and analysis. Two-way ANOVA was used to determine the effect of the genotype and diet with the Prism 4.0 software (GraphPad Software).
For repeated-measures analysis, ANOVA was used when values over different times were analyzed. Significant effects were evaluated, followed with Fisher's protected least significant difference post hoc test with Tukey or Bonferroni's correction. When only two groups were analyzed, statistical significance was determined by unpaired Student's t test. A value of p < 0.05 was considered statistically significant. All data are shown as mean ± SEM. 
